위마비 치료제 시장 : 세계 예측(2026-2032년)

The Gastroparesis Drugs Market is projected to grow by USD 7.97 billion at a CAGR of 7.27% by 2032.

Gastroparesis Drugs Executive Summary

Gastroparesis drugs address a chronic gastric motility disorder in which delayed gastric emptying occurs without mechanical obstruction, leading to nausea, vomiting, early satiety, bloating, abdominal pain, malnutrition risk, impaired glycemic control, and repeated healthcare utilization. The therapeutic landscape is shaped by high unmet need, particularly among people with diabetes, post-surgical complications, idiopathic disease, neurologic conditions, and medication-associated gastric dysmotility. Current pharmacologic management relies on prokinetic agents, antiemetics, neuromodulators used for symptom control, and supportive nutritional strategies, while clinical development increasingly focuses on targeted mechanisms that improve gastric accommodation, antral contractility, pyloric function, and nausea pathways. The themes defining the gastroparesis drugs industry include diabetic gastroparesis treatment, idiopathic gastroparesis therapy, prokinetic drugs, antiemetic treatment, gastric motility therapeutics, enteral nutrition support, and novel gastroenterology drug development. Demand for safer long-term therapies remains strong because several available treatments carry limitations related to neurological adverse effects, cardiac safety monitoring, restricted duration of use, variable symptom response, and off-label prescribing practices.

Transformative Shifts in the Gastroparesis Drugs Landscape

The gastroparesis drugs landscape is undergoing a structural shift from broad symptom suppression toward mechanism-informed, patient-segmented therapy. Clinical practice is increasingly differentiating diabetic, idiopathic, post-surgical, neurologic, and medication-induced gastroparesis because underlying pathophysiology and treatment response can differ substantially. Wider use of gastric emptying scintigraphy, breath testing, wireless motility capsule assessment where available, and standardized symptom scoring is improving diagnostic consistency and patient stratification. Another major shift is the growing recognition of drug-induced delayed gastric emptying, especially as incretin-based metabolic therapies become more widely used for diabetes and obesity management; this is increasing the need for medication review, risk stratification, and coordinated care between gastroenterology, endocrinology, nutrition, and primary care. Therapeutic development is also moving beyond traditional dopamine antagonist and macrolide approaches toward agents targeting ghrelin receptors, serotonin pathways, neurokinin-mediated nausea, pyloric dysfunction, and central-peripheral gut-brain signaling. Regulatory expectations continue to emphasize clinically meaningful symptom improvement, validated patient-reported outcomes, safety in chronic use, and evidence across heterogeneous patient populations. Together, these shifts are raising the bar for gastroparesis drug innovation and supporting more integrated care models.

Cumulative Impact of Artificial Intelligence on Gastroparesis Drugs

Artificial intelligence is increasingly influencing gastroparesis drug discovery, clinical trial design, diagnosis support, and real-world evidence generation. In discovery, AI-enabled screening and molecular modeling can help identify compounds affecting motility pathways, receptor selectivity, nausea signaling, and safety liabilities earlier in development. In clinical operations, machine learning can support patient enrichment by integrating symptom patterns, gastric emptying results, diabetes status, medication history, autonomic neuropathy indicators, nutritional markers, and prior treatment response. This is particularly relevant because gastroparesis trials often face heterogeneous disease biology and fluctuating symptom severity. In care delivery, AI-assisted analytics can help flag patients at risk of delayed diagnosis, dehydration, malnutrition, emergency visits, or medication-related worsening of gastric emptying. Natural language processing of clinical notes may improve identification of under-coded cases, while remote monitoring tools can capture vomiting frequency, oral intake, glucose variability, weight change, and patient-reported outcomes. However, AI adoption in gastroparesis drugs must address data quality, representativeness, clinical validation, explainability, privacy compliance, and bias mitigation. The cumulative impact is a more evidence-driven ecosystem in which drug developers, clinicians, and payers can better connect therapeutic mechanisms with measurable patient outcomes.

Key Regional Insights Across Gastroparesis Drug Adoption

In Asia-Pacific, rising diabetes prevalence, expanding specialist gastroenterology services, and growing access to diagnostic testing are increasing attention to diabetic gastroparesis drugs and motility disorder management, with China, India, Japan, South Korea, and Australia serving as important centers for clinical capability, digital health adoption, and regulatory activity. North America remains highly influential because of advanced diagnostic infrastructure, established specialty care pathways, active clinical research participation, and heightened awareness of treatment limitations, particularly in chronic prokinetic and antiemetic use. Latin America is characterized by improving access to gastroenterology services in urban centers, a high burden of diabetes in several countries, and growing need for affordable symptomatic management, although disparities in gastric emptying diagnostics and specialist referral remain key barriers. Europe emphasizes guideline-driven care, pharmacovigilance, and safety monitoring, with national health systems supporting structured approaches to diabetic complications, functional gastrointestinal disorders, and gastrointestinal motility disorders. The Middle East is seeing increasing relevance of gastroparesis therapeutics as diabetes and obesity-related metabolic disease remain prominent public health priorities, especially in Gulf economies with expanding tertiary care networks and specialty clinics. Africa presents an emerging but uneven landscape where diabetes recognition is increasing, yet access to gastric emptying diagnostics, specialist motility services, enteral nutrition support, and advanced pharmacologic options can be limited, creating demand for scalable diagnosis, essential medication access, and practical care pathways.

Key Group Insights for Gastroparesis Drugs

ASEAN countries are becoming more relevant to gastroparesis drug access as diabetes care expands and urban healthcare systems improve gastrointestinal diagnostic capacity, though affordability, reimbursement depth, and specialist availability vary across member states. The GCC demonstrates strong strategic relevance because high diabetes prevalence, investment in advanced hospitals, and expanding specialty care support greater recognition of diabetic gastroparesis and related pharmacologic needs. The European Union offers a highly regulated environment in which drug safety, post-marketing surveillance, harmonized evidence standards, and health technology assessment influence access to gastroparesis therapies and chronic-use medications. BRICS economies bring together large patient populations, rising metabolic disease burden, expanding domestic clinical research ecosystems, and variable reimbursement structures, making evidence generation, cost-effectiveness, and local regulatory alignment essential. G7 countries typically anchor advanced gastroenterology research, validated clinical endpoints, pharmacovigilance systems, and payer scrutiny, which together shape global expectations for gastroparesis drug efficacy, safety, and patient-reported outcomes. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where secure pharmaceutical supply chains, regulatory coordination, hospital readiness, and specialty treatment access remain important considerations for chronic gastrointestinal motility disorder management.

Key Country Insights in Gastroparesis Drug Demand

The United States has a well-developed gastroparesis care environment supported by specialist motility centers, broad clinical trial activity, and strong awareness of diabetic and idiopathic gastroparesis, while safety concerns around long-term prokinetic use continue to shape prescribing decisions. Canada emphasizes evidence-based treatment, access through provincial systems, and specialist referral pathways, with ongoing need to improve timely diagnosis and equitable access across geographies. Mexico and Brazil face substantial diabetes-related care needs, making affordable gastroparesis symptom management, improved diagnostic access, and clinician education important priorities. The United Kingdom, Germany, France, Italy, and Spain reflect mature European care settings where gastroenterology guidelines, medicine safety oversight, and reimbursement review influence the adoption of prokinetics, antiemetics, and emerging therapies. Russia presents a large treatment population with variable access to specialized diagnostic infrastructure across regions. China and India are central to future disease recognition because of large diabetes populations, expanding hospital networks, and growing demand for gastrointestinal therapeutics, although rural-urban access gaps remain important. Japan has long-standing expertise in functional gastrointestinal disorders and gastric motility research, supporting sophisticated clinical understanding of symptom-based treatment and safety monitoring. Australia benefits from strong specialist care and guideline-oriented management, while South Korea combines advanced hospital systems, digital health adoption, and active interest in gastrointestinal innovation, making it an important country for gastroparesis drugs and motility-focused therapeutics.

Actionable Recommendations for Gastroparesis Drug Leaders

Industry leaders should prioritize development programs that clearly distinguish diabetic, idiopathic, post-surgical, neurologic, and medication-associated gastroparesis because differentiated patient populations can improve endpoint selection and therapeutic positioning. Clinical trials should combine objective measures of gastric emptying with validated symptom scores, nutrition-related outcomes, rescue medication use, glycemic control markers where relevant, and quality-of-life measures to demonstrate meaningful benefit. Safety strategy is critical, particularly for therapies intended for chronic use, and should include neurological, cardiovascular, metabolic, and drug-interaction monitoring where relevant. Organizations should invest in real-world evidence partnerships with gastroenterology, endocrinology, and nutrition networks to better understand treatment pathways, discontinuation drivers, emergency care utilization, and patient-reported disease burden. Digital tools can strengthen adherence tracking, symptom diaries, dehydration alerts, dietary monitoring, and remote follow-up, but should be clinically validated and designed for patient usability. Market access planning should focus on unmet need, reduction in acute care utilization, nutritional stabilization, and suitability for long-term management rather than relying on broad symptomatic claims. Education initiatives should help clinicians recognize gastroparesis earlier, assess medication-induced delayed emptying, and coordinate multidisciplinary treatment.

Research Methodology for Evidence-Based Gastroparesis Drug Insights

This executive summary is developed through secondary research and evidence synthesis using publicly available, verifiable sources such as peer-reviewed medical literature, clinical practice guidelines, regulatory safety communications, clinical trial registries, disease burden publications, and healthcare policy references. The methodology prioritizes data-backed interpretation of disease epidemiology drivers, diagnostic standards, therapeutic mechanisms, clinical unmet needs, safety considerations, regional healthcare access patterns, and regulatory factors affecting gastroparesis drugs. Insights were cross-checked across gastroenterology, endocrinology, pharmacology, clinical nutrition, and health systems sources to maintain consistency and avoid unsupported claims. The analysis deliberately excludes market estimation, market sizing, market share calculation, and forecasting, focusing instead on qualitative industry intelligence, treatment landscape assessment, and evidence-based strategic implications. Regional, group, and country insights were developed by mapping gastroparesis relevance to diabetes burden, diagnostic infrastructure, specialist availability, medicine access, regulatory maturity, pharmacovigilance expectations, and healthcare system capacity.

Conclusion

Gastroparesis drugs remain an important area of gastroenterology innovation because current treatment options often provide incomplete relief and can be constrained by safety, tolerability, and duration-of-use limitations. The strongest opportunities lie in therapies that address defined mechanisms of delayed gastric emptying and nausea while demonstrating durable symptom improvement, acceptable chronic-use safety, and measurable patient-centered outcomes. Regional growth in diabetes care, improved diagnostic awareness, and expanding specialty services are increasing recognition of gastroparesis across both mature and emerging healthcare systems. Artificial intelligence, real-world evidence, and digital symptom monitoring are likely to strengthen patient identification, trial efficiency, and post-treatment assessment when implemented responsibly. Industry stakeholders that combine rigorous clinical evidence, differentiated patient segmentation, safety-focused development, and practical access strategies will be best positioned to meet unmet needs in diabetic gastroparesis, idiopathic gastroparesis, and broader gastric motility disorder treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastroparesis Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Dopamine Antagonists
  • 7.2.1. Cisapride
  • 7.2.2. Domperidone
  • 7.2.3. Metoclopramide
• 7.3. Motilin Receptor Agonists
  • 7.3.1. Azithromycin
  • 7.3.2. Erythromycin
• 7.4. Serotonin Receptor Agonists
  • 7.4.1. Granisetron
  • 7.4.2. Ondansetron

8. Gastroparesis Drugs Market, by Disease Type

• 8.1. Introduction
• 8.2. Diabetic Gastroparesis
• 8.3. Idiopathic Gastroparesis
• 8.4. Postsurgical Gastroparesis

9. Gastroparesis Drugs Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral
• 9.4. Transdermal

10. Gastroparesis Drugs Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Home Care Settings
• 10.4. Hospitals

11. Gastroparesis Drugs Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Gastroparesis Drugs Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Gastroparesis Drugs Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Gastroparesis Drugs Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amneal Pharmaceuticals, Inc.
• 16.4. ANI Pharmaceuticals, Inc.
• 16.5. AstraZeneca PLC
• 16.6. Atlantic Healthcare PLC
• 16.7. Bausch Health Companies Inc.
• 16.8. Bristol-Myers Squibb Company
• 16.9. Cadila Pharmaceuticals Limited
• 16.10. Cairn Diagnostics
• 16.11. Evoke Pharma, Inc.
• 16.12. GlaxoSmithKline PLC
• 16.13. Johnson & Johnson Services, Inc.
• 16.14. Kyowa Kirin International plc
• 16.15. Lupin Limited
• 16.16. Medtronic PLC
• 16.17. Neurogastrx, Inc.
• 16.18. Novartis AG
• 16.19. Pfizer, Inc.
• 16.20. Processa Pharmaceuticals, Inc.
• 16.21. Sanofi S.A.
• 16.22. Takeda Pharmaceutical Company Limited
• 16.23. Theravance Biopharma
• 16.24. Vanda Pharmaceuticals Inc.
• 16.25. Viatris Inc.